Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey in Arthritis and Rheumatology
2022
AOU Città della Salute di Torino
Tipo pubblicazione
Conference Abstract
Autori/Collaboratori (50)Vedi tutti...
Thakare D
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Naveen R
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Pauling J
North Bristol NHS Trust, Bristol, United Kingdom
et alii...
Abstract
Background/Purpose: Dedicated data on COVID-19 vaccine-related adverse events (ADEs) in patients with systemic sclerosis (SSc) is limited. Therefore, we aimed to compare all patient-reported ADEs post-COVID-19 vaccination in patients with SSc with those in healthy controls (HCs) or non-SSc autoimmune rheumatic diseases (NS-AIRDs). Methods: Data from the international patient-reported online survey on COVID-19 Vaccination in Autoimmune Diseases (COVAD) study conducted in 2021 by more than 110 collaborators across 94 countries was analyzed. Major and minor ADEs following receipt of COVID-19 vaccine were compared between patients with SSc, those with NS-AIRDs, or with other autoimmune diseases (AIDs) and HCs. Multivariable regression analysis adjusting for age, gender, ethnicity, vaccine type, and immunosuppressants received were performed. Results: Of the 10,679 respondents (Table 1), there were 478 SSc patients (4.4%) with a mean (SD) age 53.8 (13.3) years, comprising 88% females. At the time of vaccination, 65% were on immunosuppressants and 24% on glucocorticoids. The most common immunosuppressant was mycophenolate mofetil (25.7%). Among the SSc patients, 83% had completed two vaccine doses. Pfizer-BioNTech (BNT162b2) (51%) and Oxford/AstraZeneca (ChAdOx1 nCoV-19) (23%) were the most common vaccines received. Vaccination related ADEs (Table 2) were reported in 81.2% of SSc patients (81.2%-minor and 3.3%-major ADEs). Patients on hydroxychloroquine reported lower fatigue [OR 0.4 (0.2-0.8)]. Major ADEs were no different across different vaccine types (Table 3). Pfizer-BioNTech (BNT162b2) recipients reported lower body ache, fever, chills, nausea, and vomiting [OR ranging 0.2-0.4]. Oxford/AstraZeneca (ChAdOx1 nCoV-19) recipients reported higher body ache, fever, chills, nausea vomiting, headache, and fatigue [OR ranging 2.0-5.1]. Moderna (mRNA-1273) recipients reported higher fever, chills, chest pain [OR ranging 2.6-8.9]. Covishield (Serum Institute India) (ChA
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.
DOI : 10.1002/art.42355
Keywords
covilo; elasomeran; glucocorticoid; hydroxychloroquine; immunosuppressive agent; mycophenolate mofetil; tozinameran; vaxzevria; adult; adverse drug reaction; autoimmune disease; chill; conference abstract; coronavirus disease 2019; drug safety; drug therapy; ethnicity; fatigue; female; fever; gender; headache; hospitalization; human; human tissue; India; injection site pain; major clinical study; male; nausea and vomiting; rheumatic disease; side effect; systemic sclerosis; thorax pain; vaccination;